渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

盘前交易 07-22 05:25:54 EDT

226.40

+1.15

+0.51%

盘前224.30

-2.10-0.93%

04:13 EDT

最高227.63	最低222.38	成交量85.18万
今开225.67	昨收225.25	日振幅2.33%
总市值329.63亿	流通市值328.48亿	总股本1.46亿
成交额1.92亿	换手率0.59%	流通股本1.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":226.4,"timestamp":1721419200000,"preClose":225.25,"halted":0,"volume":851787,"hourTrading":{"tag":"盘前","latestPrice":224.3,"preClose":226.4,"latestTime":"04:13 EDT","volume":193,"amount":43264.47611,"timestamp":1721636020178},"delay":0,"floatShares":145087014,"shares":145596895,"eps":8.003279,"marketStatus":"盘前交易","marketStatusCode":1,"change":1.15,"latestTime":"07-22 05:25:54 EDT","open":225.67,"high":227.625,"low":222.38,"amount":192083189.95431,"amplitude":0.023285,"askPrice":228.71,"askSize":2,"bidPrice":226.29,"bidSize":2,"shortable":3,"etf":0,"ttmEps":8.003279,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721655000000},"adr":0,"listingDate":685080000000,"adjPreClose":226.4,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":224.3,"preClose":226.4,"latestTime":"04:13 EDT","volume":193,"amount":43264.47611,"timestamp":1721636020178},"postHourTrading":{"tag":"盘后","latestPrice":226.4,"preClose":226.4,"latestTime":"19:16 EDT","volume":36869,"amount":8347359.3272,"timestamp":1721430970915},"volumeRatio":0.7515362241305763,"impliedVol":0.3733,"impliedVolPercentile":0.932},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"2451955251","title":"诺和诺德支持瑞士生物技术公司 Asceneuron 完成 1 亿美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2451955251","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451955251?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:00","pubTimestamp":1721113208,"startTime":"0","endTime":"0","summary":" Maggie Fick    路透伦敦7月16日 - 瑞士生物技术公司Asceneuron周二表示，它已从包括Wegovy生产商诺和诺德公司控股股东在内的投资者那里筹集到1亿美元，用于资助其阿尔茨海默病药物的临床开发。Asceneuron公司的领先实验药物ASN51属于一类新药，被称为O-GlcNA酶 抑制剂。一周前，诺和诺德控股公司牵头为英国生物技术公司Myricx Pharma单独进行了一轮9000万英镑，以推进其实验性癌症药物的研发。诺和诺德控股公司的投资资金也在不断增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","LU0208291251.USD","LU0154236417.USD","LU0672654240.SGD","LU0965509101.SGD","LU0070302665.USD","IE00B19Z9Z06.USD","LU0266013472.USD","IE00B894F039.SGD","IE00BZ1G4Q59.USD","LU1267930730.SGD","LU0965509010.AUD","LU1037948897.HKD","LU1585245621.USD","LU1974910355.USD","IE00BK4W5L77.USD","IE00BLSP4239.USD","LU0965508806.USD","MRK","BK4588","LU1430594728.SGD","IE00BN8TJ469.HKD","LU0965509283.SGD","IE00B4R5TH58.HKD","LU0238689110.USD","IE00BLSP4452.SGD","NVO","LU0456855351.SGD","LU1941712348.USD","BIIB","LU0320765059.SGD","LU0471298777.SGD","LU1037948541.HKD","LU0417517546.SGD","LU1941712264.USD","LU1023059063.AUD","LU0289739699.SGD","LU1934455277.USD","LU0234572021.USD","LU1934455194.USD","BK4581","LU0234570918.USD","LU0265550946.USD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LLY","LU0256863902.USD","LU1291159041.SGD","IE00BK4W5M84.HKD","BK4139"],"gpt_icon":0},{"id":"2450258160","title":"BUZZ--美国股票走势-特斯拉、泰克资源、摩根大通","url":"https://stock-news.laohu8.com/highlight/detail?id=2450258160","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450258160?lang=zh_cn&edition=full","pubTime":"2024-07-12 20:01","pubTimestamp":1720785716,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      7月12日 - 周五，美国股指期货在寻找方向的斗争中挣扎，投资者在分析一系列大银行财报以衡量美国企业的健康状况的同时，也在等待关键的通胀数据，以寻找降息时机的线索。美东时间7:34，道指电子盘  上涨0.06%，报40,113点。标普500指数小型股  上涨0.05%，报5,642.75点；纳斯达克100指数小型股  持平，报20,440.75点。","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","IE00BLSP4452.SGD","LU0208291251.USD","BK4532","LU1914381329.SGD","LU0128525689.USD","BK","IE00B894F039.SGD","BK4548","LU0082616367.USD","BK4504","LU0053666078.USD","LU0234570918.USD","IE00B19Z3B42.SGD","BK4574","JPM","BK4527","BK4534","LU0211327993.USD","LU1699723380.USD","BIIB","LU1429558221.USD","LU0251131958.USD","TSLA","LU1548497426.USD","ASPI","IE00B1XK9C88.USD","IE0002270589.USD","LU0234572021.USD","LU1267930227.SGD","LU0238689110.USD","LU1791807156.HKD","BK4139","LU0267386448.USD","BK4109","LU0106831901.USD","BK4501","LU0289960550.SGD","LU1435385759.SGD","LU0130102774.USD","IE00BWXC8680.SGD","LU0251142724.SGD","LU1280957306.USD","BK4581","LU0316494557.USD","LU1551013425.SGD","IE00BJTD4N35.SGD","LU0211326755.USD","LU0648001328.SGD","LU2357305700.SGD"],"gpt_icon":0},{"id":"2450583897","title":"BUZZ-派珀-桑德勒下调百健公司的目标价，预计阿尔茨海默氏症药物Leqembi的接受度不高","url":"https://stock-news.laohu8.com/highlight/detail?id=2450583897","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450583897?lang=zh_cn&edition=full","pubTime":"2024-07-12 18:55","pubTimestamp":1720781735,"startTime":"0","endTime":"0","summary":"    7月12日 - ** 券商Piper Sandler将百健  的股票交易价格从335美元下调至313美元，同时下调了该公司阿尔茨海默病 药物Leqembi的近期和长期销售前景。** 经纪公司称，虽然准入限制有所放宽，但医生们仍对安全性、输液物流以及该药物的预期疗效表示担忧。** 现将 Leqembi 公司 24 年第二季度的营业额预测从 490 万美元下调至 3000 万美元，并下调了第三季度和第四季度的预测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","LLY","BUZZ"],"gpt_icon":0},{"id":"2448449335","title":"BMO：礼来(LLY.US)阿尔茨海默氏症药有望创收71亿美元 优于渤健(BIIB.US)竞品","url":"https://stock-news.laohu8.com/highlight/detail?id=2448449335","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448449335?lang=zh_cn&edition=full","pubTime":"2024-07-04 11:59","pubTimestamp":1720065555,"startTime":"0","endTime":"0","summary":"智通财经获悉，据BMO报道，礼来公司 最新获批准的阿尔茨海默病药物donanemab可能为该公司带来高达71亿美元的峰值销售额，并将有助于该制药商的收入来源多样化。礼来公司表示，符合条件的患者可以获得医疗保险覆盖和报销。该药物预计将与日本卫材医药和渤健的同类药物Leqembi竞争，Leqembi于2023年获得FDA批准。礼来公司的乳腺癌药物Verzenio以39亿美元的销售额位居第三。礼来2023年的总收入为340亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","IE00B1BXHZ80.USD","LU2237443622.USD","LU0114720955.EUR","LU2237443978.SGD","LU1804176565.USD","LU0079474960.USD","LU0417517546.SGD","LU2237443382.USD","LU0943347566.SGD","BK4534","LU0238689110.USD","LU2491050071.SGD","BK4007","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0234570918.USD","LU1023059063.AUD","LU0708995401.HKD","BK4581","BK4533","LU0058720904.USD","BMO","LU0061475181.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","IE00B894F039.SGD","LLY","LU1551013342.USD","LU1551013425.SGD","LU0256863811.USD","LU2237443549.SGD","LU2468319806.SGD","LU0122379950.USD","BK4532","LU1814569148.SGD","LU2264538146.SGD","IE0004445239.USD","GB00BDT5M118.USD","LU1988902786.USD","LU0289739699.SGD","LU1280957306.USD","LU2491049909.HKD","LU0882574055.USD","IE00BJT1NW94.SGD","LU0672654240.SGD","BIIB","LU2237438978.USD","LU0109391861.USD"],"gpt_icon":0},{"id":"2448104359","title":"背景资料-礼来紧随百健-艾赛之后，获得美国食品及药物管理局对阿尔茨海默氏症药物的批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2448104359","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448104359?lang=zh_cn&edition=full","pubTime":"2024-07-03 20:18","pubTimestamp":1720009106,"startTime":"0","endTime":"0","summary":"     路透7月3日 -    礼来公司  的Kisunla周二获得了美国食品和药物管理局的标准批准，用于减缓阿尔茨海默氏症的进展。Kisunla是继百健  和日本卫材  的Leqembi之后，第二种获得美国监管机构传统批准的治疗脑萎缩疾病的药物，这在一个经历了多次失败的领域是一个重要的里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU1814569148.SGD","LU0708995401.HKD","IE0004445239.USD","ACW.AU","BIIB","IE00B19Z9P08.USD","LU0061475181.USD","BK4007","CGTX","LU2491049909.HKD","LGVN","LU0122379950.USD","LU1988902786.USD","ACIU","IE00B894F039.SGD","GB00BDT5M118.USD","LU1057294990.SGD","LU0256863811.USD","ANVS","LU1551013425.SGD","LLY","BK4533","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU1804176565.USD","LU0058720904.USD","LU2237443978.SGD","LU2264538146.SGD","BK4534","IE00BJT1NW94.SGD","BIVI","LU2237438978.USD","COYA","LU2237443549.SGD","LU2237443382.USD","LU0320765992.SGD","IE00B1BXHZ80.USD","LU0079474960.USD","IE0002141913.USD","LU0882574055.USD","LU2468319806.SGD","LU2491050071.SGD","BK4532","LU1280957306.USD","LU2237443622.USD","LU0109391861.USD","LU1551013342.USD","BK7067","LU0943347566.SGD"],"gpt_icon":0},{"id":"2448773691","title":"BUZZ-券商观点：礼来的阿尔茨海默氏症药物获批也可能使百健受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2448773691","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448773691?lang=zh_cn&edition=full","pubTime":"2024-07-03 18:02","pubTimestamp":1720000945,"startTime":"0","endTime":"0","summary":"    7月3日 - ** 美国食品和药物管理局周二批准了  礼来公司的  治疗早期阿尔茨海默氏症的药物，该药物的品牌名称为Kisunla，这是将向美国患者提供的第二种减缓这种脑损伤疾病进展的疗法。** BMO Capital Markets 称，预计 Kisunla 的销售峰值将达到 71 亿美元，这将使该公司在本十年后半期的收入实现多样化。** Truist Securities 称，Kisunla的差异化特征有可能降低总体治疗成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU0672654240.SGD","LU1804176565.USD","LU2491050071.SGD","LU0882574055.USD","LU0943347566.SGD","LU0061475181.USD","LU2237438978.USD","LLY","LU2237443549.SGD","LU1551013342.USD","IE00B894F039.SGD","IE00BJJMRZ35.SGD","IE00B19Z9P08.USD","LU0079474960.USD","LU0122379950.USD","LU0114720955.EUR","LU2237443622.USD","LU2468319806.SGD","BK4533","LU0109391861.USD","IE0004445239.USD","IE00B1BXHZ80.USD","LU1988902786.USD","LU0417517546.SGD","BK4007","LU2237443978.SGD","BK4581","LU0058720904.USD","IE0002141913.USD","IE00B19Z9Z06.USD","BK4532","LU0708995401.HKD","LU1023059063.AUD","LU1057294990.SGD","LU1551013425.SGD","LU1814569148.SGD","LU2237443382.USD","BUZZ","LU2491049909.HKD","LU0256863811.USD","IE00BJT1NW94.SGD","GB00BDT5M118.USD","LU0320765992.SGD","LU0289739699.SGD","BIIB","LU1280957306.USD","BK4534","LU2264538146.SGD","LU0238689110.USD"],"gpt_icon":0},{"id":"2448119882","title":"礼来(LLY.US)阿尔茨海默氏症药获美国FDA批准 与渤健(BIIB.US)展开两强争霸！","url":"https://stock-news.laohu8.com/highlight/detail?id=2448119882","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448119882?lang=zh_cn&edition=full","pubTime":"2024-07-03 08:06","pubTimestamp":1719965170,"startTime":"0","endTime":"0","summary":"智通财经获悉，礼来研发的药物“donanemab-azbt”被美国食品和药物管理局批准用于治疗有轻度认知障碍的阿尔茨海默病早期患者，商品名为“Kisunla”。根据阿尔茨海默病协会的数据，近700万美国人患有这种疾病，是65岁以上老年人的第五大死因。“双雄争霸”阿尔茨海默病治疗领域Donanemab将与渤健及其日本合作伙伴卫材药业的另一种治疗药物Leqembi展开正面竞争。FDA因在2021年加速批准Aduhelm而受到批评，尽管咨询小组提出了负面建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4534","LU1551013342.USD","LU1623119135.USD","LU1814569148.SGD","LU2237443549.SGD","LU0122379950.USD","LU2237443382.USD","LU0256863811.USD","LU2264538146.SGD","IE00BJT1NW94.SGD","BK4532","LU1551013425.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2491049909.HKD","LU1988902786.USD","LU0385154629.USD","LU0097036916.USD","LU0061475181.USD","LU2491050071.SGD","IE0002141913.USD","LU0289739699.SGD","LU1804176565.USD","BK4533","LU2237443978.SGD","LU0708995401.HKD","LU1023059063.AUD","LU1280957306.USD","LU1712237335.SGD","LU2265009873.SGD","LU0943347566.SGD","IE00B1BXHZ80.USD","BIIB","IE00B894F039.SGD","GB00BDT5M118.USD","LU0689472784.USD","LU1057294990.SGD","IE0009355771.USD","LU0820561909.HKD","LU0114720955.EUR","BK4007","IE00B19Z9P08.USD","LU2237443622.USD","LU0079474960.USD","LU0320765992.SGD","LU0882574055.USD","LU0058720904.USD","LLY","LU0109391861.USD","IE0004445239.USD"],"gpt_icon":0},{"id":"2446513977","title":"卫材与百健联合在中国推出阿尔茨海默氏症药物乐清碧","url":"https://stock-news.laohu8.com/highlight/detail?id=2446513977","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446513977?lang=zh_cn&edition=full","pubTime":"2024-06-28 08:48","pubTimestamp":1719535689,"startTime":"0","endTime":"0","summary":"    路透6月28日 - 卫材  和百健  周五表示，它们已在中国推出阿尔茨海默氏症治疗药物Leqembi，中国是继美国和日本之后的第三个国家。Leqembi通过清除大脑中一种叫做β淀粉样蛋白的有毒蛋白质而发挥作用，它是第一种被证实能改变这种致命性脑损伤疾病病程的阿尔茨海默氏症治疗药物。卫材公司还与中国一家大型医疗保险公司合作，计划承担部分药费，但未透露保险公司名称。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4533","BK4139","IE00B19Z9P08.USD","LU0109394709.USD","IE00B19Z9Z06.USD","BK4585","BK4532","LU0234570918.USD","IE00B894F039.SGD","LU0889565916.HKD","LU0320765992.SGD","BK4588"],"gpt_icon":0},{"id":"2446111826","title":"媒体-百健下一步并购赌注高达 100 亿美元--彭博新闻社","url":"https://stock-news.laohu8.com/highlight/detail?id=2446111826","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446111826?lang=zh_cn&edition=full","pubTime":"2024-06-26 00:19","pubTimestamp":1719332399,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    6月25日 - -- 来源链接：  -- 注：路透未核实此报道，不保证其准确性","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0320765992.SGD","BK4585","BK4533","LU0889565916.HKD","IE00B19Z9Z06.USD","BIIB","BK4139","IE00B19Z9P08.USD","LU0109394709.USD","IE00B894F039.SGD","BK4588","LU0234570918.USD"],"gpt_icon":0},{"id":"2442587286","title":"更新 5-礼来阿尔茨海默氏症药物获得 FDA 顾问小组一致支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2442587286","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442587286?lang=zh_cn&edition=full","pubTime":"2024-06-11 05:48","pubTimestamp":1718056097,"startTime":"0","endTime":"0","summary":"几位专家组成员指出，对于有两个 APOE4 基因拷贝的人来说，安全问题更为突出，因为这种基因拷贝与更高的阿尔茨海默氏症风险有关。礼来公司说，它正计划在有阿尔茨海默氏症遗传倾向的患者中进行试验，测试这种治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","BK4534","LU0943347566.SGD","LU2237443622.USD","LU1267930730.SGD","LU1988902786.USD","BIIB","LU0640476718.USD","LU1057294990.SGD","BK4588","LU2237443382.USD","LU2491050071.SGD","IE0002141913.USD","IE0004445239.USD","LU1804176565.USD","IE00B1BXHZ80.USD","BK4007","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU0238689110.USD","LU0708995401.HKD","LU0882574139.USD","GB00BDT5M118.USD","IE00B2B36J28.USD","LU0320765059.SGD","LU1551013342.USD","LU2237438978.USD","LU0820561818.USD","IE00B19Z9P08.USD","BK4532","LU0058720904.USD","BK4581","BK4533","LU0289739699.SGD","LU1712237335.SGD","LU2468319806.SGD","LU0234570918.USD","LU0109394709.USD","LU1064131342.USD","LU0889565916.HKD","LLY","LU0097036916.USD","LU0256863811.USD","LU2264538146.SGD","IE00BFTCPJ56.SGD","BK4139","LU2237443978.SGD","LU2265009873.SGD","LU2491049909.HKD","LU0122379950.USD"],"gpt_icon":1},{"id":"2442284834","title":"美国食品和药物管理局顾问将审查礼来公司的阿尔茨海默氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2442284834","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442284834?lang=zh_cn&edition=full","pubTime":"2024-06-10 19:00","pubTimestamp":1718017235,"startTime":"0","endTime":"0","summary":" Bhanvi Satija/Julie Steenhuysen    路透6月10日 - 美国食品和药物管理局的一个独立顾问小组将于周一晚些时候就礼来公司  的阿尔茨海默氏症试验性药物多奈单抗的安全性和有效性进行投票表决。礼来公司的这种药物和其他同类药物可能导致致命的脑肿胀或脑出血。至少有四位华尔街分析师上周表示，美国食品及药物管理局的审查人员 ，没有提出任何严重的警示，他们预计donanemab将获得批准。据阿尔茨海默氏症协会称，超过 600 万美国人患有某种形式的破坏记忆的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","IE0002141913.USD","IE00B19Z9P08.USD","IE00B1BXHZ80.USD","LU0320765992.SGD","LU1804176565.USD","LU1551013342.USD","LU1551013425.SGD","LU0061475181.USD","LLY","LU2237443549.SGD","LU2468319806.SGD","LU2491049909.HKD","LU2491050071.SGD","LU2491050154.USD","LU1023059063.AUD","LU0234570918.USD","LU0256863811.USD","BK4007","LU0289739699.SGD","LU2264538146.SGD","LU0238689110.USD","GB00BDT5M118.USD","LU1057294990.SGD","BK4532","LU0114720955.EUR","IE0004445239.USD","LU0708995401.HKD","BK4534","LU2237438978.USD","BIIB","LU2237443382.USD","LU1988902786.USD","IE00BJT1NW94.SGD","IE00B894F039.SGD","LU2237443978.SGD","LU0122379950.USD","LU0943347566.SGD","BK4533","IE00BJJMRZ35.SGD","LU0417517546.SGD","LU1280957306.USD","LU2237443622.USD","BK4581","LU0672654240.SGD","LU0058720904.USD","LU0882574055.USD","LU1814569148.SGD","LU0109391861.USD","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2441710171","title":"更新版 1-美国 FDA 专家小组将就礼来老年痴呆症药物的数据和安全性进行投票表决","url":"https://stock-news.laohu8.com/highlight/detail?id=2441710171","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441710171?lang=zh_cn&edition=full","pubTime":"2024-06-06 21:56","pubTimestamp":1717682196,"startTime":"0","endTime":"0","summary":"     路透6月6日 - 美国卫生监管机构的一个外部专家小组将于周一召开会议，就礼来   的多那单抗的安全性和疗效数据进行投票，并向FDA提出建议，该药是卫材  和百健  的Leqembi的潜在竞争对手。该机构网站周四公布的文件显示，该小组还将就治疗的益处是否大于风险进行投票。阿尔茨海默氏症试验曾发现该类药物存在脑肿胀和出血等安全隐患。在礼来公司的试验中，有三名参与者死于与治疗有关的并发症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1551013342.USD","LU1623119135.USD","LU1814569148.SGD","LU2237443549.SGD","LU0122379950.USD","LU2237443382.USD","LU0256863811.USD","LU2264538146.SGD","IE00BJT1NW94.SGD","BK4532","LU1551013425.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2491049909.HKD","LU1988902786.USD","LU0097036916.USD","LU0061475181.USD","LU2491050071.SGD","IE0002141913.USD","LU0289739699.SGD","BK4588","BK4581","LU1804176565.USD","BK4533","LU2237443978.SGD","LU0708995401.HKD","LU1023059063.AUD","LU1280957306.USD","LU1712237335.SGD","LU0943347566.SGD","IE00B1BXHZ80.USD","LU2491050154.USD","BIIB","IE00B894F039.SGD","GB00BDT5M118.USD","LU1057294990.SGD","IE0009355771.USD","LU0820561909.HKD","LU0114720955.EUR","BK4007","IE00B19Z9P08.USD","LU2237443622.USD","LU0079474960.USD","LU0320765992.SGD","LU0882574055.USD","LU0058720904.USD","LLY","LU0109391861.USD","IE0004445239.USD"],"gpt_icon":0},{"id":"2439601669","title":"欧盟执委会批准百健公司 ALS 药物上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2439601669","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439601669?lang=zh_cn&edition=full","pubTime":"2024-05-31 06:04","pubTimestamp":1717106694,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月30日 - 百健  周四称，欧盟执委会在特殊情况下批准了其肌萎缩性脊髓侧索硬化症(ALS) 药物Qalsody的上市许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","LU0320765992.SGD","LU0889565916.HKD","LU0234570918.USD","LU0109394709.USD","IE00B19Z9P08.USD","BK4533","BK4139","BIIB","IE00B19Z9Z06.USD","BK4588","BK4585","BK4532"],"gpt_icon":0},{"id":"2439573704","title":"加拿大皇家银行：重申Biogen(BIIB.US)评级，由优于大市调整至优于大市评级, 目标价317.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2439573704","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439573704?lang=zh_cn&edition=full","pubTime":"2024-05-29 22:16","pubTimestamp":1716992190,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：重申Biogen(BIIB.US)评级，由优于大市调整至优于大市评级, 目标价317.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405292216329f00087b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405292216329f00087b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB"],"gpt_icon":0},{"id":"2438346146","title":"卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病抗体新药在韩国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2438346146","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438346146?lang=zh_cn&edition=full","pubTime":"2024-05-28 15:52","pubTimestamp":1716882757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月27日，卫材和渤健宣布，韩国食品药品安全部已批准人源化抗可溶性β淀粉样蛋白(Aβ)单克隆抗体lecanemab上市，用于治疗早期(轻度)阿尔茨海默病或由阿尔茨海默病引起的轻度认知障碍成人患者。根据卫材新闻稿，这是继美国、日本、中国之后，lecanemab在第四个国家获批上市。此外，卫材已经于近日向美国FDA滚动递交用于每周维持给药的lecanemab-irmb皮下注射剂的BLA，此前该药物被FDA授予快速审评通道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4533","IE00B894F039.SGD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0109394709.USD","IE00B19Z9P08.USD","LU0320765992.SGD","BK4585","BIIB","BK4139","BK4588","BK4532","LU0889565916.HKD"],"gpt_icon":0},{"id":"2438817234","title":"Biogen Inc-在韩国卫材韩国公司将分销产品并开展信息提供活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2438817234","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438817234?lang=zh_cn&edition=full","pubTime":"2024-05-27 07:44","pubTimestamp":1716767095,"startTime":"0","endTime":"0","summary":"Biogen Inc-在韩国卫材韩国公司将分销产品并开展信息提供活动","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405270744589eef94f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405270744589eef94f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","BK4588","IE00B894F039.SGD","BK4532","BIIB","IE00B19Z9Z06.USD","BK4139","LU0109394709.USD","IE00B19Z9P08.USD","BK4533","LU0234570918.USD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2437739378","title":"HC Wainwright & Co.：重申Biogen(BIIB.US)评级，由买入调整至买入评级, 目标价300.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2437739378","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437739378?lang=zh_cn&edition=full","pubTime":"2024-05-23 18:16","pubTimestamp":1716459396,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Biogen(BIIB.US)评级，由买入调整至买入评级, 目标价300.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052318164195530150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052318164195530150&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIIB"],"gpt_icon":0},{"id":"2437298181","title":"百健(BIIB.US)将以18亿美元收购免疫药物开发商 HI-Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2437298181","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437298181?lang=zh_cn&edition=full","pubTime":"2024-05-22 21:04","pubTimestamp":1716383053,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百健周三宣布，已同意以高达18亿美元的价格收购Human Immunology Biosciences ，这是一家专注于严重免疫介导疾病的私营药物开发商。根据条款，百健将支付11.5亿美元的预付款，以及高达6.5亿美元的潜在里程碑付款，以收购HI-Bio。目前正在进行 felzartamab 治疗 IgA 肾病  的 2 期试验，IgAN 是慢性肾病的主要原因。百健表示，该交易预计将于2024年第三季度完成，不会影响其此前发布的2024年业绩指引。该公司打算用现金和循环信贷协议中的潜在新债务为此次交易融资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0234570918.USD","LU2125154935.USD","BIIB","BK4588","BK4533","BK4585","LU0128526141.USD","LU0109394709.USD","IE00B19Z9P08.USD","LU0889565916.HKD","BK4139","HI","BK4532","LU2125154778.USD","BK4161","LU0029874061.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU2360032135.SGD"],"gpt_icon":0},{"id":"2437616392","title":"更新版 1-百健公司将以最高 18 亿美元收购人类免疫学生物科学公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2437616392","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437616392?lang=zh_cn&edition=full","pubTime":"2024-05-22 19:48","pubTimestamp":1716378534,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (添加第2段起的详细信息)    路透5月22日 - 百健  周三表示，它已同意以高达18亿美元的价格收购私人控股的人类免疫学生物科学公司（Human Immunology Biosciences），从而获得针对严重免疫相关疾病患者的靶向疗法。这笔交易包括 11.5 亿美元的预付款和高达 6.5 亿美元的潜在里程碑付款，如果人类免疫学公司的主导产品单克隆抗体 felzartamab 达到某些开发里程碑的话。此次收购正值百健公司力图超越神经系统疾病治疗领域，扩大其罕见病药物组合之际。两家公司预计将在第三季度完成交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BIIB","BK4588","BK4585","IE00B19Z9P08.USD","LU0320765992.SGD","LU0109394709.USD","IE00B894F039.SGD","BK4533","LU0889565916.HKD","BK4532","BK4139","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2437643261","title":"Biogen Inc-Biogen预计将用现金为收购融资还可能利用其循环信贷协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2437643261","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437643261?lang=zh_cn&edition=full","pubTime":"2024-05-22 19:45","pubTimestamp":1716378349,"startTime":"0","endTime":"0","summary":"Biogen Inc-Biogen预计将用现金为收购融资还可能利用其循环信贷协议","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052219455087875fa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052219455087875fa8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4532","BK4533","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","BK4585","LU0234570918.USD","BIIB","BK4588","IE00B894F039.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":0.0123},{"period":"3month","weight":0.1647},{"period":"6month","weight":-0.0943},{"period":"1year","weight":-0.1758},{"period":"ytd","weight":-0.1251}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，他们收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.042714},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.004267},{"month":3,"riseRate":0.515152,"avgChangeRate":-0.023197},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.018344},{"month":5,"riseRate":0.606061,"avgChangeRate":0.032222},{"month":6,"riseRate":0.484848,"avgChangeRate":0.01808},{"month":7,"riseRate":0.666667,"avgChangeRate":0.036911},{"month":8,"riseRate":0.59375,"avgChangeRate":0.032796},{"month":9,"riseRate":0.5,"avgChangeRate":0.024456},{"month":10,"riseRate":0.545455,"avgChangeRate":0.062497},{"month":11,"riseRate":0.606061,"avgChangeRate":0.016153},{"month":12,"riseRate":0.484848,"avgChangeRate":0.038726}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}